Previous 10 | Next 10 |
Stoke Therapeutics press release ( NASDAQ: STOK ): Q3 GAAP EPS of -$0.66 beats by $0.02 . Revenue of $2.91M beats by $0.19M . As of September 30, 2022, Company had $252.2M in cash, cash equivalents, marketable securities, and restricted cash, anticipated to fun...
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will hold a webinar and conference call for analysts and inve...
– ADOA is primarily caused by mutations in the OPA1 gene that result in progressive and irreversible vision loss in both eyes starting in the first decade of life – – The FALCON study is designed to evaluate disease progression and its effects on patients ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Although the general rule of thumb is to avoid equities with heavy short interest, the new normal has brought with it new paradigms. One of these fresh approaches urges speculators to acquire short-squeeze stocks in a...
Stoke Therapeutics press release ( NASDAQ: STOK ): Q2 GAAP EPS of -$0.63 beats by $0.05 . Revenue of $3.2M beats by $0.18M . As of June 30, 2022, Company had $276.2 million in cash, cash equivalents, marketable securities, and restricted cash, anticipated to fu...
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the 2022 Jefferies Healthcare Conference on W...
Stoke Therapeutics press release (NASDAQ:STOK): Q1 GAAP EPS of -$0.66 misses by $0.98. As of March 31, 2022, Company had $293.8 million in cash, cash equivalents, marketable securities, and restricted cash, anticipated to fund operations into 2025. Revenue of $3M misses by $34.5M. For furth...
ACADIA Pharma's (NASDAQ:ACAD) Q1 2022 results missed on the top and bottom lines, but the company reiterated previous guidance ranges. ACADIA's (ACAD) net loss widened ~70% to ~$113M ($0.70 per share) compared to the prior-year period. The company attributed the increase a $60M upfront paymen...
– Data presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting support the Company’s work to advance STK-002 as the first potential disease modifying treatment for Autosomal Dominant Optic Atrophy (ADOA) – – ADOA ...
– New preclinical data support the ongoing preclinical development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA) – – ADOA is the most common inherited optic nerve disorder – Stoke Therapeutics, Inc. (Nasdaq: S...
News, Short Squeeze, Breakout and More Instantly...
Stoke Therapeutics Inc. Company Name:
STOK Stock Symbol:
NYSE Market:
Stoke Therapeutics Inc. Website:
2024-06-16 20:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the following upcoming investor conferences: Goldma...
2024-05-16 08:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...